Clinical trials: Lewy Body Dementia
Dementia With Lewy Bodies (DLB), Alzheimer's Disease (AD)
Contribution of Pathological Alpha-synuclein as a Diagnostic Biomarker for Dementia With Lewy Bodies
Alzheimer's disease and dementia with Lewy bodies (DLB) are the two main age-related neurodegenerative cognitive disorders. Differential diagnosis between these conditions is challenging, both at the prodromal and dementia…
- Trial name
- QuIC-Lewy (NCT07166744)
- Testing
- Biological : blood sampling, nasopharyngeal swab, Procedure : Lumbar puncture
- Volunteers
- 286 people
- Sponsor
- University Hospital, Strasbourg, France
Frontotemporal Dementia, Dementia
Care of Persons With Dementia in Their Environments (COPE) in Programs of All-Inclusive Care of the Elderly (PACE)
The protocol is organized into three Phases - In Phase I an online training program will be developed in "Care of Persons with Dementia in their Environments" (COPE) -an evidence-based bio-behavioral dementia program -using…
- Conditions
- Frontotemporal Dementia, Dementia, Multi-Infarct Dementia, Vascular Dementia
- Trial name
- NCT04165213
- Testing
- Care of Older Persons in their Environment (COPE) online module training
- Where
- United States
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Dementia-related Psychosis
Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis
The purpose of this study is to evaluate the efficacy of pimavanserin compared to placebo in preventing relapse of psychotic symptoms in subjects with dementia-related psychosis who responded to 12 weeks of open label…
- Trial name
- NCT03325556
- Testing
- Pimavanserin 34 mg, Pimavanserin 20 mg
- Where
- 83 sites in United States, Bulgaria and 11 more
- Volunteers
- 392 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Parkinson Disease, Dementia, Lewy Body
Music Therapy to Prevent Hospital-acquired Delirium in Parkinson's Disease and Dementia With Lewy Bodies
The goal of this clinical trial is to test whether a music therapy intervention (MT) prevents hospital-acquired delirium (HaD) in patients with Parkinson's disease (PD) and Dementia with Lewy Bodies (DLB).
- Conditions
- Parkinson Disease, Dementia, Lewy Body, Delirium
- Trial name
- NCT06063161
- Testing
- Music therapy intervention, Standard Care (in control arm)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Massachusetts, Worcester
Amnesia, Alzheimer Disease
OCT-Angiography and Adaptive Optics in Patients With Memory Impairment
Studies suggest an association between retinal abnormalities and NCD (Neuro Cognitive Disorders) whether they are linked to proven or prodromal Alzheimer's disease (aMCI : amnestic mild cognitive impairment), or to other…
- Conditions
- Amnesia, Alzheimer Disease, Lewy Body Disease, Parkinsons Disease With Dementia
- Trial name
- OCTAVO (NCT04389437)
- Testing
- Ophthalmological exam, Blood pressure measurement
- Where
- France
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Parkinson Disease, Progressive Supranuclear Palsy
Speech Accessibility Project
The goal of the Speech Accessibility Project at the University of Illinois Beckman Institute (https://speechaccessibilityproject.beckman.illinois.edu) is to collect, annotate, and curate a shared database of speech samples from…
- Conditions
- Parkinson Disease, Progressive Supranuclear Palsy, Multiple System Atrophy, Dementia With Lewy Bodies
- Trial name
- SAP (NCT05889260)
- Where
- 2 sites in United States
- Volunteers
- 485 people
- Sponsor
- University of Illinois at Urbana-Champaign
Frontotemporal Degeneration (FTD), ALS (Amyotrophic Lateral Sclerosis)
Biofluid Research on Age-Related or Inherited Neurodegeneration
The aim of this study is to contribute to and continue to sustain a repository of blood samples, nucleic acid (DNA and/or RNA) samples, family history information, and other demographic information from individuals with…
- Conditions
- Frontotemporal Degeneration (FTD), ALS (Amyotrophic Lateral Sclerosis), Primary Progressive Aphasia (PPA), Familial Frontotemporal Lobar Degeneration (fFTLD)
- Trial name
- BRAIN (NCT07798700)
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Parkinson Disease
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of anle138b in Parkinson's Disease
The purpose of this study is to determine the safety, tolerability and blood levels of orally administered anle138b as well as the effect of food and early signs of efficacy in patients with mild to moderate Parkinson´s disease.
- Trial name
- NCT04685265
- Testing
- anle138b
- Where
- United Kingdom
- Volunteers
- 70 people
- Sponsor
- MODAG GmbH
Alzheimer Disease, FTD
Omics Sciences for the Identification of Pathogenetic Mechanisms and Biomarkers in Neurodegenerative Diseases
The study aims to use 'omics' sciences, employing the most advanced technologies currently available, in order to identify pathogenic genomic variants, proteins and/or altered molecular pathways in neurodegenerative diseases and…
- Conditions
- Alzheimer Disease, FTD, Young-onset Dementia, MCI
- Trial name
- NeurOmics (NCT07235111)
- Where
- Italy
- Volunteers
- 1,200 people
- Sponsor
- Ospedale Policlinico San Martino
Dementia, Frontotemporal, Alzheimer Dementia (AD)
Investigating Genetic Status in Patients Presenting to Clinic
The causes of neurodegenerative dementias such as Frontotemporal Dementia, Lewy Body Disease and Alzheimer's disease are still largely unknown.
- Conditions
- Dementia, Frontotemporal, Alzheimer Dementia (AD), Lewy Body Dementia (LBD)
- Trial name
- NCT05911932
- Testing
- Biosample collection.
- Where
- Canada
- Volunteers
- 1,000 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Dementia With Lewy Bodies, Degeneration Nerves
Visualising Cerebral and Peripheral Cholinergic Nerves in Patients With Dementia Lewy Bodies.
Lewy Body Dementia (DLB) is the second most common type of neurodegenerative dementia and characterized by loss of cholinergic neurons in the cerebrum and possibly also internal organs.
- Conditions
- Dementia With Lewy Bodies, Degeneration Nerves, Positron-Emission Tomography, Acetylcholine
- Trial name
- NCT04291144
- Testing
- PET-CT using FEOBV, MRI-scan, Cognitive assessment
- Where
- Denmark
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Parkinson Disease Dementia, Dementia With Lewy Bodies
ATH-1017 Treatment in Subjects With Parkinson's Disease Dementia or Dementia With Lewy Bodies (SHAPE Trial)
This study is designed to evaluate the safety and treatment effects of fosgonimeton (ATH-1017) in subjects with Parkinson's Disease Dementia or Dementia with Lewy Bodies, with a randomized treatment duration of 26 weeks.
- Trial name
- NCT04831281
- Testing
- ATH-1017
- Where
- 10 sites in United States
- Volunteers
- 28 people
- Sponsor
- LeonaBio
Progressive Supranuclear Palsy(PSP), Dementia With Lewy Bodies (DLB)
Digital Health Technologies for Progressive Supranuclear Palsy and Dementia With Lewy Bodies
Progressive supranuclear palsy (PSP), mild cognitive impairment with Lewy bodies (MCI-LB), and Dementia with Lewy Bodies (DLB) are severe neurodegenerative diseases that cause significant motor impairment impacting daily…
- Conditions
- Progressive Supranuclear Palsy(PSP), Dementia With Lewy Bodies (DLB), PSP, Lewy Body Dementia (LBD)
- Trial name
- NCT07240805
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- BioSensics
Mild Cognitive Impairment, Alzheimer Disease
Development of an EEG Diagnostic for Alzheimer's Disease
The purpose of this research is to collect and compare electroencephalogram data from all stages of Alzheimer's disease from preclinical through severe dementia.
- Conditions
- Mild Cognitive Impairment, Alzheimer Disease, Dementia With Lewy Bodies, Normal Control APOE e4 Carriers and Noncarriers
- Trial name
- NCT04954183
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Mayo Clinic
PARKINSON DISEASE (Disorder), Atypical Parkinsonism
Early Molecular Biomarkers for Differentiating Parkinsonian Syndromes
This prospective observational study aims to identify and preliminarily validate molecular biomarkers, including microRNAs and metabolites, for the early differentiation of Parkinson's disease (PD) from atypical parkinsonian…
- Conditions
- PARKINSON DISEASE (Disorder), Atypical Parkinsonism, Multiple System Atrophy, Progressive Supranuclear Palsy (PSP)
- Trial name
- BIOMARK-PS (NCT07604883)
- Where
- 2 sites in Poland
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- International Institute of Molecular and Cell Biology in Warsaw
Alzheimer's Disease, Mild Cognitive Impairment
BEAM: Brain-Eye Amyloid Memory Study
The main objectives for this study are: 1. To investigate novel, non-invasive ocular measurements including optical coherence tomography and eye tracking in a cross-sectional study of participants with various neurodegenerative…
- Conditions
- Alzheimer's Disease, Mild Cognitive Impairment, Vascular Cognitive Impairment, Parkinson's Disease
- Trial name
- BEAM (NCT02524405)
- Testing
- Pittsburgh Compound B [11C]-PIB
- Where
- 5 sites in Canada
- Volunteers
- 345 people, healthy volunteers welcome
- Sponsor
- Sunnybrook Health Sciences Centre
Alzheimer Disease, Lewy Body Dementia (LBD)
The Role of Advanced Electroencephalographic Data as Marker of Pathology and Prognosis in Primary Dementias
The study aims to use advanced brainwave recordings of electroencephalogram (EEG) to understand early signs of Alzheimer's disease (AD) in people with mild memory problems, known as amnestic Mild Cognitive Impairment (MCI).
- Conditions
- Alzheimer Disease, Lewy Body Dementia (LBD), Mild Alzheimer Disease, Frontotemporal Dementia (FTD)
- Trial name
- NCT06826157
- Testing
- Electroencephalogram, 3 Tesla MRI, Apolipoprotein E genetic test
- Where
- Italy
- Volunteers
- 175 people, healthy volunteers welcome
- Sponsor
- IRCCS San Raffaele
Lewy Body Dementia
A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)
A randomized placebo-controlled trial to evaluate the safety and efficacy of three doses of study drug LY3154207 treated for 12 weeks in participants with mild-to-moderate dementia associated with LBD (PDD or DLB).
- Trial name
- PRESENCE (NCT03305809)
- Testing
- LY3154207
- Where
- 77 sites in United States, Canada and 1 more
- Volunteers
- 344 people
- Sponsor
- Eli Lilly and Company